Tag: Meglumine antimoniate

Leishmaniasis is a tropical disease affecting hundreds of thousands of people annually worldwide, causing a wide range of clinical presentations. The drug Glucantime (meglumine antimoniate), a pentavalent antimonial, has been a cornerstone in treating this parasitic infection for decades.

Glucantime is a crucial first-line treatment for leishmaniasis in many parts of the world, with its effectiveness dependent on its specific chemical composition. Understanding what are the ingredients in Glucantime is essential for patients and clinicians, as its formulation includes both an active component and inactive substances.

Leishmaniasis is a neglected tropical disease often impacting impoverished communities, and a significant barrier to treatment is drug accessibility and cost. The cost of Glucantime, a key medication, varies drastically depending on region, distribution channel, and procurement method, highlighting vast inequities in access to life-saving treatment.